Skip to main content
  • Experimental Therapeutic Lepodisiran Reduced Lipoprotein(a) Up to 94% at 48 Weeks: Phase I Study

    A single dose of a new small-interfering RNA therapeutic, lepodisiran, reduced the level of harmful risk factor lipoprotein(a) [Lp(a)] by up to 94% for nearly 1 year in subjects with high Lp(a) concentration and without cardiovascular disease, according to a new study.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details